This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Karges, B. Articles by Karges, W. Search for Related Content PubMed PubMed Citation Articles by Karges, B. Articles by Karges, W. Related Collections Pediatric Endocrinology Thyroid Autoimmunity

Levothyroxine in Euthyroid Autoimmune Thyroiditis and Type 1 Diabetes: A Randomized, Controlled Trial

Division of Pediatric Endocrinology and Diabetes (B.K., J.A., A.R., K.M.D., E.H.), University Children’s Hospital Ulm, D-89075 Ulm, Germany; Institute of Biometrics (R.M.) and Division of Endocrinology (B.O.B.), Clinic for Internal Medicine I, University of Ulm, D-89081 Ulm, Germany; University Children’s Hospital Erlangen (I.K.), D-91054 Erlangen, Germany; Children’s Hospital Heidenheim (W.E.), D-89505 Heidenheim, Germany; Children’s Hospital Datteln (T.W.), D-45711 Datteln, Germany; University Children’s Hospital Tübingen (R.H., A.N.), D-72076 Tübingen, Germany; Children’s Hospital Chemnitz (A.K.), D-09009 Chemnitz, Germany; Department of Nuclear Medicine (A.S.), University of Würzburg, D-97080 Würzburg, Germany; and Division of Endocrinology and Diabetes (W.K.), RWTH Aachen University, D-52074 Aachen, Germany

Address all correspondence and requests for reprints to: Beate Karges, M.D., Division of Pediatric Endocrinology and Diabetes, University Children’s Hospital, University of Ulm, Eythstrasse 24, D-89075 Ulm, Germany. E-mail: beate.karges{at}uniklinik-ulm.de.

Context: Patients with type 1 diabetes (T1D) have an increased risk of autoimmune thyroiditis (AIT).

Objective: Our objective was to determine whether levothyroxine (L-T₄) treatment prevents the clinical manifestation of AIT in euthyroid subjects with T1D.

Design and Setting: We conducted a prospective, randomized, open, controlled clinical trial at six tertiary care centers for pediatric endocrinology and diabetes.

Patients: Of 611 children and adolescents with T1D, 89 individuals (14.5%) were identified with positive thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb), or both. Of these, 30 patients (age, 13.3 ± 2.1 yr) met the inclusion criteria and were randomized to receive L-T₄ (n = 16 patients) or no treatment (n = 14 patients).

Intervention: L-T₄ (1.3 µg/kg daily) was given for 24 months in the treatment group, followed by an additional observation period of 6 months in both groups.

Main Outcome Measures: Thyroid gland volume (as determined by ultrasound), serum levels of TSH, thyroid hormones, TPOAb, and TgAb were assessed every 6 months for 30 months.

Results: Mean thyroid volume decreased in the treatment group after 24 months (–0.60 SD score) and increased in the observation group (+ 1.11 SD score; P = 0.0218). Serum thyrotropin, free T₄, TPOAb, and TgAb levels were not significantly different in both groups during the entire study period. Hypothyroidism developed in three individuals treated with L-T₄ and in four untreated patients (conversion rate, 9.3% per year).

Conclusions: In this study in euthyroid patients with AIT and T1D, L-T₄ treatment reduced thyroid volume but had no effect on thyroid function and serum autoantibody levels.